ClinicalTrials.gg
RecruitingNCT07413796NEURO-SUTUREUpdated Nov 16, 2026

Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures

An interventional study of Absorbable running intradermal suture and Non-absorbable interrupted transdermal suture in Brain Tumor Adult, Brain Tumor Benign and Meningioma, sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Medical University of Warsaw · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Brain Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 2 of them phase 3. Brain Neoplasms · Poland.

Planned enrollment
6th of 21
382 · median 245
Started
2026
with 1 other
No phase
5 of 24
3 open now
Registered
23rd of 24
by date
Lead sponsor
2 of 24
Medical University of Warsaw

Among the 24 studies in Brain Neoplasms with a site in Poland, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 23rd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 24 studies in Brain Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Brain Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to compare two commonly used methods of closing the skin after surgery for an intracranial tumor. Skin closure is one of the most important steps in neurosurgical procedures, as it has a major influence on how well the wound heals. In patients with brain tumors, proper wound healing is especially important because it may affect how soon additional treatments, such as radiotherapy or chemotherapy, can be started.

There are different ways to close the skin after surgery, including running sutures and interrupted sutures. Both methods are widely used and considered safe. However, in oncological neurosurgery, there is limited scientific evidence comparing their effects, and the choice of technique is often based on the surgeon's personal experience. In this study, investigators will compare skin closure using running absorbable sutures with interrupted non-absorbable sutures. Investigators will evaluate how well, depending on used suturing methods, the wound heals and how often wound-related complications occur, such as infection, separation of the wound edges, or leakage of cerebrospinal fluid. Investigators believe that the results of this study will help improve wound care in patients undergoing neurosurgical treatment for brain tumors and, as a result, may contribute to better recovery and overall quality of life.

03

Conditions studied

  • Brain Tumor Adult
  • Brain Tumor Benign
  • Meningioma
  • Glioma
  • Glioblastoma

Keywords

  • skin closure
  • brain tumor
  • intracranial tumor
  • glioma
  • meningioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years old
  • Qualified for a craniotomy due to supratentorial intracranial tumor

Exclusion criteria

Exclusion Criteria:

  • Revision surgery due to recurrent brain tumor
  • Emergency neurosurgical procedure
  • Scalp incision involving glabrous skin (e.g. forehead) or facial regions (e.g. eyebrow)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
382 participants (estimated)

Study arms

  • Experimental
    Subjects receiving absorbable running intradermal sutures

    Other: Absorbable running intradermal suture

  • Active comparator
    Subjects receiving non-absorbable interrupted transdermal sutures

    Other: Non-absorbable interrupted transdermal suture

Interventions

  • OtherAbsorbable running intradermal suture

    Absorbable sutures used to perform continuous/running intradermal skin closure.

  • OtherNon-absorbable interrupted transdermal suture

    Non-absorbable sutures used to perform interrupted transdermal skin closure.

06

What researchers measure

Primary outcomes

  1. Occurrence of surgical wound healing complication.

    The primary outcome of this trial is the occurrence of surgical wound healing complication including wound dehiscence (defined as separation of wound edges longer than 1 cm), surgical site infection or external cerebrospinal fluid leak.

    Time frame: From enrollment to the final wound assessment time point - 90 days postoperatively.

Secondary outcomes

  1. Aesthetic quality of wound healing - observer perspective.

    Aesthetic quality of postoperative wound/scar, evaluated using the Patient and Observer Scar Assessment Scale (from 9 to 45 points for Observer score) where higher scores indicate worse healing outcomes.

    Time frame: From enrollment to the final wound assessment time point - 90 days postoperatively.

  2. Aesthetic quality of wound healing - patient perspective.

    Aesthetic quality of postoperative wound/scar, evaluated using the Patient and Observer Scar Assessment Scale (from 17 to 85 points for Patient score) where higher scores indicate worse healing outcomes.

    Time frame: From enrollment to the final wound assessment time point - 90 days postoperatively.

  3. Aesthetic quality of wound healing - observer perspective.

    Aesthetic quality of postoperative wound/scar using Visual Analogue Scale (from 1 to 10 pints) in observer's perspective where higher score indicates better wound healing outcomes.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  4. Aesthetic quality of wound healing - patient perspective.

    Aesthetic quality of postoperative wound/scar using Visual Analogue Scale (from 1 to 10 points) in patient's perspective where higher score indicates better wound healing outcomes.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  5. Pain or discomfort related to sutures removal

    Pain/discomfort during sutures removal assessed using Visual Analogue Scale (from 1 to 10 points) among subjects receiving non-absorbable sutures where higher score stands for the worst pain ever felt.

    Time frame: At the time of non-absorbable sutures removal - typically 7-10 days postoperatively.

  6. Incidence and nature of additional interventions - invasive interventions - sutures.

    Incidence and nature of additional invasive interventions due to suboptimal wound/scar formation: \- placement of additional sutures within the wound. Amount of sutures added and timing of sutures placement after primary surgical intervention.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  7. Incidence and nature of additional interventions - invasive interventions - lumbar drainage.

    Incidence and nature of additional invasive interventions due to suboptimal wound/scar formation: \- lumbar drainage placement Timing of lumbar drainage placement after primary surgical intervention and it's duration.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  8. Incidence and nature of additional interventions - invasive interventions - secondary surgical intervention.

    Incidence and nature of additional invasive interventions due to suboptimal wound/scar formation: \- secondary surgical intervention (re-operation). Timing of secondary surgical intervention after primary surgical intervention.

    Time frame: From enrollment to the final woun assessment timepoint - 90 days postoperatively.

  9. Incidence and nature of additional interventions - conservative management

    Incidence and nature of additional conservative management interventions due to suboptimal wound/scar formation, such as: antibiotic therapy and/or pharmacologic therapy - type of drugs used for management and it's duration.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively

  10. Incidence of external cerebrospinal fluid leak

    Incidence of cerebrospinal fluid leakage through the wound margins.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  11. Surgical site infections - deep infections.

    Incidence of deep surgical site infections, based on clinical and/or radiologic evaluation, such as epidural/subdural empyema, intracranial abscess.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  12. Surgical site infections - superficial infections requiring hospitalization.

    Incidence of superficial surgical site infections, based on clinical and/or radiologic evaluation such as skin erythema, swelling, tenderness, purulent/serous discharge skin necrosis that require hospitalization. Evaluation of timing of infections diagnoses after primary surgical intervention.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  13. Surgical site infections - superficial infections not requiring hospitalization.

    Incidence of superficial surgical site infections, based on clinical and/or radiologic evaluation such as skin erythema, swelling, tenderness, purulent/serous discharge skin necrosis that do not require hospitalization. Evaluation of timing of infections diagnoses after primary surgical intervention.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  14. Economic Evaluation - cost of materials used for interrupted skin closure.

    Cost of materials used in patients whose skin was closed using interrupted non-absorbable sutures.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

  15. Economic Evaluation - cost of materials used for continuous skin closure.

    Costs of skin closure materials used in patients whose skin was closed using using the continuous absorbable suture.

    Time frame: From enrollment to the final wound assessment timepoint - 90 days postoperatively.

07

Study locations

2 of 2 sites recruiting
  • Department of Neurosurgery and Pediatric Neurosurgery
    Lublin, Lublin Voivodeship 20-090, Poland
    Recruiting
  • Department of Neurosurgery of Medical University of Warsaw
    Warsaw, Masovian Voivodeship 02-097, Poland
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 24 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 17, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Feb 2028
CompletionEst.
May 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Department of Neurosurgery and Pediatric Neurosurgery · Lublin, Poland
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added
    Show site
    • Department of Neurosurgery and Pediatric Neurosurgery · Lublin, Poland
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07413796
Collaborators
Medical University of Lublin
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 1, 2026
Primary completion
Feb 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Michał Senger, M.D.
Contact
michal.senger@wum.edu.pl
+48 791 760 040
Michał Senger, M.D.
principal investigator · Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland
Tomasz A Dziedzic, M.D. Phd
principal investigator · Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion